Cargando…

Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer

BACKGROUND: In the PAOLA-1 trial, olaparib plus bevacizumab demonstrated significant clinical benefit following partial or complete response to platinum-based chemotherapy in homologous recombination deficiency (HRD)-positive ovarian cancer. Our study evaluated the cost effectiveness of olaparib plu...

Descripción completa

Detalles Bibliográficos
Autores principales: Elsea, David, Fan, Lin, Mihai, Adela, Moustaid, Fadoua El, Simmons, Daniel, Monberg, Matthew, Muston, Dominic
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596645/
https://www.ncbi.nlm.nih.gov/pubmed/36036344
http://dx.doi.org/10.1007/s41669-022-00338-2
_version_ 1784815914761322496
author Elsea, David
Fan, Lin
Mihai, Adela
Moustaid, Fadoua El
Simmons, Daniel
Monberg, Matthew
Muston, Dominic
author_facet Elsea, David
Fan, Lin
Mihai, Adela
Moustaid, Fadoua El
Simmons, Daniel
Monberg, Matthew
Muston, Dominic
author_sort Elsea, David
collection PubMed
description BACKGROUND: In the PAOLA-1 trial, olaparib plus bevacizumab demonstrated significant clinical benefit following partial or complete response to platinum-based chemotherapy in homologous recombination deficiency (HRD)-positive ovarian cancer. Our study evaluated the cost effectiveness of olaparib plus bevacizumab compared with bevacizumab alone as a maintenance treatment for women in this population. METHODS: Our model was a cohort-level partitioned survival model with a lifetime horizon from a US healthcare system perspective. Its four health states were progression-free, post first progression, post second progression, and death, modeled using time to first progression (PFS1), second progression (PFS2), and overall survival (OS) from PAOLA-1. We modeled PFS1 through mixture survival modeling, and PFS2 and OS by fitting standard parametric models. Time-on-treatment was sourced directly from PAOLA-1, with treatment capped at 24 months for olaparib and 15 months for bevacizumab. Costs included drug acquisition and administration, adverse events, disease management, biomarker testing, and subsequent treatments. Deterministic and probabilistic sensitivity analyses tested the results. RESULTS: Compared with bevacizumab alone, olaparib plus bevacizumab increased quality-adjusted life-years (QALYs; +2.89) and life-years (LYs; +3.43) at an incremental cost of $164,209, leading to an incremental cost-effectiveness ratio of $56,863 per QALY. Olaparib plus bevacizumab had a 97.0% probability of being cost effective compared with bevacizumab alone at a willingness-to-pay threshold of $100,000 per QALY. CONCLUSION: The addition of olaparib to bevacizumab led to clinically significant increases in progression-free survival, resulting in substantial predicted LYs and QALYs gained, while being cost effective in the maintenance treatment of advanced ovarian cancer with HRD in the US. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s41669-022-00338-2.
format Online
Article
Text
id pubmed-9596645
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-95966452022-10-27 Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer Elsea, David Fan, Lin Mihai, Adela Moustaid, Fadoua El Simmons, Daniel Monberg, Matthew Muston, Dominic Pharmacoecon Open Original Research Article BACKGROUND: In the PAOLA-1 trial, olaparib plus bevacizumab demonstrated significant clinical benefit following partial or complete response to platinum-based chemotherapy in homologous recombination deficiency (HRD)-positive ovarian cancer. Our study evaluated the cost effectiveness of olaparib plus bevacizumab compared with bevacizumab alone as a maintenance treatment for women in this population. METHODS: Our model was a cohort-level partitioned survival model with a lifetime horizon from a US healthcare system perspective. Its four health states were progression-free, post first progression, post second progression, and death, modeled using time to first progression (PFS1), second progression (PFS2), and overall survival (OS) from PAOLA-1. We modeled PFS1 through mixture survival modeling, and PFS2 and OS by fitting standard parametric models. Time-on-treatment was sourced directly from PAOLA-1, with treatment capped at 24 months for olaparib and 15 months for bevacizumab. Costs included drug acquisition and administration, adverse events, disease management, biomarker testing, and subsequent treatments. Deterministic and probabilistic sensitivity analyses tested the results. RESULTS: Compared with bevacizumab alone, olaparib plus bevacizumab increased quality-adjusted life-years (QALYs; +2.89) and life-years (LYs; +3.43) at an incremental cost of $164,209, leading to an incremental cost-effectiveness ratio of $56,863 per QALY. Olaparib plus bevacizumab had a 97.0% probability of being cost effective compared with bevacizumab alone at a willingness-to-pay threshold of $100,000 per QALY. CONCLUSION: The addition of olaparib to bevacizumab led to clinically significant increases in progression-free survival, resulting in substantial predicted LYs and QALYs gained, while being cost effective in the maintenance treatment of advanced ovarian cancer with HRD in the US. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s41669-022-00338-2. Springer International Publishing 2022-08-29 /pmc/articles/PMC9596645/ /pubmed/36036344 http://dx.doi.org/10.1007/s41669-022-00338-2 Text en © Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A. 2022, corrected publication 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research Article
Elsea, David
Fan, Lin
Mihai, Adela
Moustaid, Fadoua El
Simmons, Daniel
Monberg, Matthew
Muston, Dominic
Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer
title Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer
title_full Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer
title_fullStr Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer
title_full_unstemmed Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer
title_short Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer
title_sort cost-effectiveness analysis of olaparib in combination with bevacizumab compared with bevacizumab monotherapy for the first-line maintenance treatment of homologous recombination deficiency-positive advanced ovarian cancer
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596645/
https://www.ncbi.nlm.nih.gov/pubmed/36036344
http://dx.doi.org/10.1007/s41669-022-00338-2
work_keys_str_mv AT elseadavid costeffectivenessanalysisofolaparibincombinationwithbevacizumabcomparedwithbevacizumabmonotherapyforthefirstlinemaintenancetreatmentofhomologousrecombinationdeficiencypositiveadvancedovariancancer
AT fanlin costeffectivenessanalysisofolaparibincombinationwithbevacizumabcomparedwithbevacizumabmonotherapyforthefirstlinemaintenancetreatmentofhomologousrecombinationdeficiencypositiveadvancedovariancancer
AT mihaiadela costeffectivenessanalysisofolaparibincombinationwithbevacizumabcomparedwithbevacizumabmonotherapyforthefirstlinemaintenancetreatmentofhomologousrecombinationdeficiencypositiveadvancedovariancancer
AT moustaidfadouael costeffectivenessanalysisofolaparibincombinationwithbevacizumabcomparedwithbevacizumabmonotherapyforthefirstlinemaintenancetreatmentofhomologousrecombinationdeficiencypositiveadvancedovariancancer
AT simmonsdaniel costeffectivenessanalysisofolaparibincombinationwithbevacizumabcomparedwithbevacizumabmonotherapyforthefirstlinemaintenancetreatmentofhomologousrecombinationdeficiencypositiveadvancedovariancancer
AT monbergmatthew costeffectivenessanalysisofolaparibincombinationwithbevacizumabcomparedwithbevacizumabmonotherapyforthefirstlinemaintenancetreatmentofhomologousrecombinationdeficiencypositiveadvancedovariancancer
AT mustondominic costeffectivenessanalysisofolaparibincombinationwithbevacizumabcomparedwithbevacizumabmonotherapyforthefirstlinemaintenancetreatmentofhomologousrecombinationdeficiencypositiveadvancedovariancancer